MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Longitudinal CSF measurements of alpha-synuclein, amyloid beta and tau in Parkinson disease

R. Miller, A. Li, M. Campbel, J. Perlmutter, P. Kotzbauer (St. Louis, USA)

Meeting: 2023 International Congress

Abstract Number: 1505

Keywords: Alpha-synuclein, Parkinson’s

Category: Parkinson's Disease: Molecular Mechanisms of Disease

Objective: To evaluate whether cerebrospinal fluid (CSF) levels of alpha synuclein (Asyn), amyloid beta (Aβ) and tau change with disease progression and to evaluate whether lower CSF Asyn levels in PD correspond to lower levels of soluble Asyn in brain tissue.

Background: Parkinson disease (PD) is defined by the accumulation of aggregated Asyn in Lewy bodies and Lewy neurites. Widespread Aβ plaque accumulation occurs in a subset of PD patients, which is typically not accompanied by widespread tau accumulation. In our previous study we observed lower CSF Asyn and  Aβ1-42 levels in PD compared to control participants, while CSF tau levels were similar between PD and control.

Method: CSF Asyn, Aβ1-42 and tau were measured using commercial ELISAs. For postmortem brain tissue measurements, we utilized an in-house sandwich ELISA to measure Asyn levels in extracts of frozen postmortem brain tissue for 5 cortical regions, two limbic regions and 1 basal ganglia region.

Results: In this follow up study, we measured baseline CSF Asyn, Aβ1-42 and tau in 190 PD and 48 control participants. Similar to the previous dataset, CSF Asyn and Aβ1-42 were significantly lower in PD compared with controls, and CSF tau was not significantly different between PD and control. CSF Asyn positively correlated with tau in PD participants and controls, but Asyn only correlated with Aβ1-42 in PD participants but not in controls. We also measured CSF Asyn, Aβ1-42 and tau in 74 PD and 23 control participants who had a second lumbar puncture (LP2) between 2 and 9 years after the baseline LP (LP1). CSF Asyn remained lower in PD compared with controls in these longitudinal samples. However there was no significant change between LP1 and LP2 for Asyn. Mean levels of soluble Asyn in 8 brain regions were similar between 6 control and 39 PD cases, and Asyn levels did not correlate with either age or disease duration.

Conclusion: These results indicate that CSF Asyn levels are lower in PD compared to control and do not change in relation to disease duration. They also indicate that lower CSF levels in PD do not directly reflect levels of soluble Asyn in brain tissue, but instead may reflect altered transport or turnover in CSF.

To cite this abstract in AMA style:

R. Miller, A. Li, M. Campbel, J. Perlmutter, P. Kotzbauer. Longitudinal CSF measurements of alpha-synuclein, amyloid beta and tau in Parkinson disease [abstract]. Mov Disord. 2023; 38 (suppl 1). https://www.mdsabstracts.org/abstract/longitudinal-csf-measurements-of-alpha-synuclein-amyloid-beta-and-tau-in-parkinson-disease/. Accessed June 15, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2023 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/longitudinal-csf-measurements-of-alpha-synuclein-amyloid-beta-and-tau-in-parkinson-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley